Quantitative assessment of 99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study

Oya, Takashi; Ichikawa, Yasutaka; Nakamura, Satsohi; Tomita, Yoya; Sasaki, Takeshi; Inoue, Takahiro; Sakuma, Hajime

doi:10.1007/s12149-023-01833-0

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SPECT/CT imaging has gradually become widely accepted in the evaluation of DTC due to its ability to accurately locate and characterize abnormal lesions with accumulated radioactive nuclides, which affects staging, risk stratification, and clinical therapy ( 17 ). With the advancement of imaging technology, quantitative parameters of SPECT/CT have become vital imaging markers for disease diagnosis ( 18 ), therapy response evaluation ( 19 , 20 ), therapy guidance ( 9 , 21 ), and disease monitoring ( 22 , 23 ). However, research on the quantitative parameters of SPECT/CT imaging 3 days after RAI adjuvant therapy has been relatively limited.…”

Section: Discussionmentioning

confidence: 99%

Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer

Mao,

Lin,

Wang

et al. 2024

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background Single-photon emission computed tomography-computed tomography (SPECT/CT) quantification has emerged as a valuable tool for assessing disease prognosis by accurately identifying and characterizing abnormal lesions with accumulated radionuclides. Papillary thyroid carcinoma (PTC) is the most prevalent type of thyroid cancer, and radioactive iodine (RAI) therapy is a standard treatment following total thyroidectomy. This study aimed to explore the potential utility the quantitative parameters of the thyroid bed under iodine-131 (I-131) SPECT/CT in the efficacy of RAI adjuvant therapy for patients with PTC. Methods The retrospective cohort study enrolled 107 patients with PTC who underwent RAI adjuvant therapy from June 2020 to January 2023. Three days after the RAI adjuvant therapy, all patients underwent I-131 whole-body scans and SPECT/CT imaging. The quantitative parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and percent injected dose (%ID), were measured using image analysis software based on I-131 SPECT/CT thyroid bed uptake. Successful therapy was defined as inhibitory thyroglobulin (Tg) <0.2 ng/mL with negative thyroglobulin antibody (TgAb) and negative imaging examination 6 months after RAI adjuvant therapy. The relationship between the quantitative parameters and the treatment efficacy, in addition to the potential influencing factors, were analyzed. Results The quantitative parameters from the successful group [SUVmax: median 6.15 g/mL, interquartile range (IQR) 2.34–13.80 g/mL; SUVmean: median 2.02 g/mL, IQR 0.89–4.93 g/mL; %ID: median 2.00%, IQR 1.00–4.00%] were significantly lower than those from the unsuccessful group (SUVmax: median 19.03 g/mL, IQR 5.31–45.10 g/mL, SUVmean 4.64 g/mL, IQR 2.07–19.05 g/mL; %ID: median 8.00%, IQR 3.00–18.00%) (SUVmax: Z=−3.755; SUVmean; Z=−3.671; %ID: Z=−4.070; all P values <0.001). SUVmax, SUVmean and %ID were positively correlated with the stimulated thyroglobulin (sTg) and inhibitory Tg at 6 months after RAI adjuvant therapy, respectively (all P values <0.001). SUVmax [odds ratio (OR) =1.045], SUVmean (OR =1.130), and %ID (OR =1.092) were predictive factors for the failure of RAI adjuvant therapy (all P values <0.001). Conclusions Our study suggested that quantitative parameters (SUVmax, SUVmean, and %ID) derived from I-131 SPECT/CT imaging of the thyroid bed can serve as useful tools for predicting therapy outcomes following RAI adjuvant therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer

Mao,

Lin,

Wang

et al. 2024

Quant Imaging Med Surg

View full text Add to dashboard Cite

show abstract

Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment

Fukai,

Daisaki,

Umeda

et al. 2024

Ann Nucl Med

View full text Add to dashboard Cite

Objective: Radium-223 is a first-line alpha-emitting radionuclide treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, and the completion and prognosis of this treatment are intensively studied. Although the spread-based bone scan index (BSI) and the novel index of intensity-based twodimensional total bone uptake (2D-TBU) from anomalous hot spot counts of bone scintigraphy may provide useful input in radium-223 treatment, they have not been evaluated in detail yet. This study aimed to fill this gap by evaluating BSI and 2D-TBU in patients treated with radium-223.Methods: Twenty-seven Japanese patients with mCRPC treated with radium-223 were retrospectively analyzed. The patients were evaluated via blood tests and bone scans at baseline and 3 cycles intervals of treatment. BSI and 2D-TBU were analyzed via VSBONE BSI in terms of correlations, response to radium-223 treatment, and association with treatment completion, and the Kaplan-Meier survival analysis was performed.Results: Nineteen patients (70.4%) completed six cycles of radium-223 treatment, whereas eight patients (29.6%) did not complete the treatment regimen. A significant difference in baseline BSI and 2D-TBU was observed between these groups of patients.Both BSI and 2D-TBU were highly correlated with treatment response (r = 0.96, p < 0.001). Univariate analysis showed an association between radium-223 completion in median BSI and 2D-TBU values (p = 0.015) and completion percentage differences (91.7% vs. 45.5%; p = 0.027). The Kaplan-Meier product limit estimator showed that the median overall survival was 25.2 months (95% CI: 14.0-33.6 months) in the completion group and 7.5 months (95% CI: 3.3-14.2 months) in the without completion group (p < 0.001). Conclusions:Both BSI and 2D-TBU showed high correlations and strong agreement with treatment response. In particular, BSI could contain information not only on the spread but also on the comprehensive active intensity of the bone metastatic burden. Furthermore, both indices were associated with treatment completion with superior prognosis in the completion group. This study supports the necessity of preliminary assessment using BSI and 2D-TBU extracted from VSBONE BSI for radium-223 treatment decisions and monitoring.

show abstract

SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Zamani-Siahkali,

Mirshahvalad,

Farbod

et al. 2024

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Quantitative assessment of 99mTc-methylene diphosphonate bone SPECT/CT for assessing bone metastatic burden and its prognostic value in patients with castration-resistant prostate cancers: initial results in a single-center retrospective study

Cited by 4 publications

References 26 publications

Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer

Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer

Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment

SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Contact Info

Product

Resources

About